

To: [Customer Name and Email Address]
From: [Sanofi Representative Name and Email Address]
Date: [Month date, year]
Subject: [Are your immunizations trailing off during RSV season?]

[ALT Subject 1: Help to increase immunization rates for RSV season]
[ALT Subject 2: Your role contributes to population health]



Help prevent RSV disease in infants with Beyfortus® and see how you can affect population health

Dear [Customer Name],

As you may know, immunizing infants to help protect against the risk of RSV disease remains important through the entirety of the RSV season. Data from the 2024-2025 RSV season showed rates of infant immunization and maternal vaccination for RSV declined during December. Data also indicated an increase in RSV hospitalization rates in the same month.^{1-3*†}



MORE can be done to help protect infants this RSV season with Beyfortus

Beyfortus is a monoclonal antibody that helps prevent RSV disease starting from **Day 1** after injection. Beyfortus has been studied in clinical trials and real-world settings for its **effectiveness against infant RSV hospitalization**. Additionally, real-world studies have evaluated **population health impact**.^{4-8§}

Your efforts in immunizing infants against RSV disease can impact the population health burden in your community. In the 2024-2025 RSV season, the combined maternal and Beyfortus coverage rate was only 53.8%, leaving every other infant vulnerable.^{2,6-8||}

It is important to **keep immunization efforts strong throughout the RSV season** to help protect infants from RSV-LRTI when they need it most.¹

INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

IMPORTANT SAFETY INFORMATION

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Please see additional Important Safety Information below.

Do you have sufficient Beyfortus inventory to last through March 31?

[ORDER NOW](#)

As a healthcare professional, you play an important role in addressing the population health burden of RSV disease. Help to maintain consistent immunization rates throughout the entirety of the RSV season.

Take the opportunity to administer Beyfortus at the hospital after birth, or at the first week well-baby visit, to help protect infants from RSV-LRTI.^{9†}

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions

- **Hypersensitivity Reactions Including Anaphylaxis:** Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
- **Use in Individuals with Clinically Significant Bleeding Disorders:** As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see full [Prescribing Information](#) or visit [Beyfortus.com](https://www.beyfortus.com)

Thank you for doing your part to help protect infants from RSV disease this season.

Please reach out if I can assist you with increasing immunization coverage over the remaining RSV season.

Best regards,

[Name]

[Title]

[Contact info]

RSV-LRTI, respiratory syncytial virus lower respiratory tract infection.

*Does not capture claims from clinics not affiliated with the American Medical Association, Kaiser, and the public. Claims capture ~90% private clinic claims and are bumped up by 10% to reflect overall market. Medical claims projected by ~35% to align on private claims market.²

†RSV claims sourced from IQVIA private medical and retail claims through February 15, 2025 (March 2025 claims data feed). IQVIA private claims are restated up to 2 months from capture owing to which weekly claim values may alter marginally in upcoming claims feeds. There is no correlation between RSV hospitalizations and IQVIA claims.²

‡There were 4,847 babies who received Synagis® that are not in this chart.²

§Estimated absorption half-life following intramuscular injection from infant pharmacokinetic analysis was 1.7 days. Time to maximum concentration is 6 days in adults.^{4,5}

||Coverage rates based on unpublished data.²

¶Beyfortus is recommended to be given at the hospital during the typical RSV season.⁹

References: 1. Immunizations to protect infants. Centers for Disease Control and Prevention. Updated August 18, 2025. Accessed December 5, 2025. <https://www.cdc.gov/rsv/vaccines/protect-infants.html> 2. Data on File. Sanofi. 3. RSV-NET. Centers for Disease Control and Prevention. Updated June 5, 2025. Accessed December 5, 2025. <https://www.cdc.gov/rsv/php/surveillance/rsv-net.html> 4. Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi. 5. Clegg L, Freshwater E, Leach A, et al. Population pharmacokinetics of nirsevimab in preterm and term infants. *J Clin Pharmacol*. 2024;64(5):555-567. 6. Mallah N, Pardo-Seco J, Pérez-Martínez O, et al; NIRSE-GAL Study Group. Full 2023-24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study. *Lancet Infect Dis*. 2025;25(2):e62-e63. 7. Mallah N, Pardo-Seco J, Pérez-Martínez O, et al; NIRSE-GAL Study Group. Full 2023-24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study. *Lancet Infect Dis*. 2025;25(2)(suppl):e62-e63. 8. Torres JP, Sauré D, Goic M, et al. Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study. *Lancet Infect Dis*. Published online June 10, 2025. Accessed December 5, 2025. 9. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. *MMWR Morb Mortal Wkly Rep*. 2023;72(34):920-925.

Prescribers and other Healthcare Professionals may go to <https://www.sanofi.us/en/our-company/governance/state-disclosure> for State Price Disclosure Information.

sanofi

SANOFI

1 Discovery Drive

Swiftwater, PA 18370

www.sanofi.us

© 2026 Sanofi. All rights reserved.

[Legal Disclaimer Information](#) and [Privacy Policy](#)

Questions or comments? Click [here](#) for customer support or call 1-855-BEYFORTUS (1-855-239-3678). This communication is intended for US Healthcare Professionals.

You may unsubscribe from Sanofi by clicking [here](#).

MAT-US-2514837-v1.0-01/2026